Our Commitment to R&D Collaboration
 - Building Value

At OncoMark, we are committed to building value through partnering via:

• Actively pursuing new licensing opportunities in cancer biomarkers.
• Biomarker validation for predictive applications, e.g. drug development.
• Biomarker validation for prognostic aplication.
• Finding suitable partners for our R&D projects.
• Co-operating with commercially well-established local partners in the countries where we do not have a direct presence.
• Sharing risk and reward for new product development.

What are our strengths and what do we offer?

• Proven R&D experience particularly devoted to cancer molecular diagnostics using tissue-based approaches.
• Proprietary research validated technology platforms for IHC quantitation & interpretation.
• Excellent know-how and resources for biomarker discovery, validation and assay development.
• Expert partners for EU projects.